Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies. Integration of Advanced Modalities: Lead adoption of molecular pathology and spatial technologies (to support translational research and broader BDR needs. Digital & Computational Pathology: Drive implementation of whole-slide imaging, AI/ML-based image analysis, and integration of spatial biomarker analytics into decision-making. Data Interpretation & Reporting: Provide expert interpretation of pathology data, ensuring robust correlation with clinical outcomes and mechanistic insights. Cross-functional Leadership: Collaborate with Translational Medicine, Bioinformatics, and Clinical Development colleagues to implement candidate biomarkers into Translational Biomarker plans for RAS(ON) inhibitors in alignment with overarching clinical development strategies.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree